Welcome to BioVaxys Technology Corp.
Investor Invitation to Virtual Investor Conference
VANCOUVER, BC , Sept. 12, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”)
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com. The company is a clinical-stage organization focusing on developing immune-educating therapies using its innovative DPX™ platform. These therapies are aimed at combating a variety of conditions including cancers, infectious diseases, and immune modulated disorders.
We are pleased to announce that our Chief Executive Officer, James Passin, has been invited to present live at the Life Sciences Investor Forum, to be hosted by VirtualInvestorConferences.com on September 19th, 2024.
This opportunity provides investors with a chance to learn more about BioVaxys’ innovative technologies and the potential impact they can have on healthcare and bioengineering industries. We look forward to sharing our vision and progress with the investment community.
How it will affect individuals
Investors who attend the presentation by BioVaxys CEO, James Passin, will gain valuable insights into the company’s cutting-edge technologies and potential for growth. This knowledge can help individuals make informed decisions about their investment portfolios and potentially benefit from the promising future of BioVaxys.
How it will affect the world
BioVaxys’ focus on developing immune-educating therapies has the potential to revolutionize the treatment of various diseases, including cancers, infectious diseases, and immune modulated disorders. By presenting at the Life Sciences Investor Forum, BioVaxys is taking a step towards gaining recognition and support for its groundbreaking research, which could ultimately lead to significant advancements in healthcare on a global scale.
Conclusion
As BioVaxys Technology Corp. gears up to present at the Life Sciences Investor Forum, we are excited to showcase our innovative DPX™ platform and the potential it holds for transforming the landscape of healthcare. We look forward to engaging with investors, advisors, and analysts at the virtual event and sharing our vision for a future where immune-educating therapies play a crucial role in combating diseases and improving patient outcomes.
